Drug Device Combination Products in Europe: A Complete Regulatory Guide

The healthcare industry is evolving rapidly, and one of the fastest-growing areas is drug device combination products. These innovative solutions bring together the therapeutic benefits of drugs with the precision and convenience of medical devices. From pre-filled insulin pens to drug-eluting stents, combination products are transforming patient care.

But with innovation comes regulatory complexity—especially in Europe. Manufacturers must navigate both medicinal product and medical device regulations, making compliance a challenging yet crucial step. In this guide, we’ll break down everything you need to know about the European framework for drug-device combination products, offering clarity for businesses, manufacturers, and regulatory professionals.

What Are Drug Device Combination Products?

Drug device combination products are therapeutic products that integrate both a medicinal substance and a medical device. They are designed to work together as a single entity, ensuring safety, efficacy, and usability for patients.

Examples include:

• Pre-filled syringes and pens (e.g., insulin pens, epinephrine auto-injectors)

• Drug-eluting stents used in cardiovascular treatments

• Inhalers delivering respiratory drugs

• Implantable devices coated with antibiotics or anti-inflammatory agents

What sets these products apart is that the drug and device components are inseparable—neither can achieve the intended purpose without the other.

Why Europe’s Regulatory Landscape Is Unique

Europe has a stringent regulatory framework to ensure that medical products are safe, effective, and consistent. Unlike in the U.S., where the FDA oversees combination products under a single umbrella, Europe requires compliance with two key systems:

1. Medicinal Product Regulation – overseen by the European Medicines Agency (EMA) and national competent authorities.

2. Medical Device Regulation (MDR 2017/745) – overseen by Notified Bodies, designated by the European Commission.

This dual oversight means manufacturers must carefully plan their regulatory strategy early in the product development process.

Classification of Drug-Device Combination Products in Europe

Combination products are classified based on their primary mode of action (PMOA):

• Medicinal product with an integral device – The drug provides the primary therapeutic effect, while the device administers it.

  • Example: a pre-filled syringe.

• Medical device incorporating a medicinal substance – The device provides the main effect, while the drug enhances safety or effectiveness.

  • Example: a drug-eluting stent.

This classification determines whether the product follows the EMA route (for drug-led products) or the MDR route (for device-led products).

Key Regulatory Requirements Under EU MDR

For medical-device-led products under MDR 2017/745, manufacturers must demonstrate compliance with strict requirements. Some highlights include:

• Clinical Evaluation – Evidence that the product performs safely and as intended.

• Risk Management – Comprehensive risk analysis covering both the drug and device elements.

• Quality Management System (QMS) – Alignment with ISO 13485 standards.

• Notified Body Opinion (NBOp) – A crucial step for devices that incorporate a medicinal substance.

Manufacturers need to request a scientific opinion from a competent authority (such as EMA) regarding the drug component, which the Notified Body integrates into its final conformity assessment.

👉 For a detailed breakdown of how to obtain this opinion, you can read this step-by-step guide on drug-device combination products.

Challenges in Regulatory Compliance

Bringing combination products to the European market is complex. Here are the most common challenges manufacturers face:

1. Dual Oversight – Navigating both EMA and Notified Body requirements.

2. Evolving Regulations – MDR has introduced stricter rules compared to the old MDD framework.

3. Scientific Opinion Timelines – Lengthy assessments can delay product launch.

4. Clinical Evidence – Demonstrating combined safety and efficacy requires robust studies.

5. Documentation Burden – Preparing technical files, risk assessments, and QMS records can overwhelm small companies.

Best Practices for Manufacturers

To succeed in Europe’s demanding regulatory environment, manufacturers should adopt a proactive strategy:

• Engage Early With Authorities – Clarify regulatory pathways before investing heavily in development.

• Develop a Strong QMS – Ensure your quality system covers both device and drug aspects.

• Plan Clinical Trials Strategically – Address both drug and device performance in a single study.

• Collaborate With Experts – Partner with regulatory consultants, such as 3iconcept medical solution, for guidance on compliance.

• Stay Updated – EU regulations continue to evolve, so monitoring updates is critical.

Future Outlook for Combination Products in Europe

The demand for drug-device combination products will only continue to grow. Factors driving this trend include:

• Personalized medicine – Devices tailored to individual patients improve outcomes.

• Chronic disease management – Integrated solutions simplify long-term therapies.

• Technological innovation – Smart devices and digital health integration are on the rise.

At the same time, regulatory scrutiny will remain high. The EU aims to balance patient safety with innovation support, making compliance expertise a competitive advantage for manufacturers.

Final Thoughts

Successfully bringing drug device combination products to the European market requires a deep understanding of both medicinal and device regulations. The dual nature of these products makes compliance complex, but with the right strategy—strong quality management, early engagement with authorities, and expert guidance—manufacturers can navigate the system effectively.

Europe’s regulatory framework is demanding, but it ultimately ensures that patients receive safe, effective, and innovative treatments. By staying ahead of requirements, companies can turn regulatory compliance into a strength rather than a hurdle.